Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma

References

• Martin SD , BhuiyanI, SoleimaniM, WangG. Biomarkers for immune checkpoint inhibitors in renal cell carcinoma. J. Clin. Med.12(15), 4987 (2023).
   PubMed Web of Science ®Google Scholar
• Chen F , ZhangY, ŞenbabaoğluYet al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell. Rep.14(10), 2476–2489 (2016).
   PubMed Web of Science ®Google Scholar
• Iacovelli R , SternbergCN, PortaCet al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr. Drug Targets16(2), 164–170 (2015).
   PubMed Web of Science ®Google Scholar
• Rini BI , AtkinsMB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol.10(10), 992–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, McdermottDFet al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , TannirNM, McdermottDFet al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med.378(14), 1277–1290 (2018).
   PubMed Web of Science ®Google Scholar
• Wong JSL , KwokGGW, TangVet al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer9(2), (2021).
   Web of Science ®Google Scholar
• Chen J , JiangCC, JinL, ZhangXD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol.27(3), 409–416 (2016).
   PubMed Web of Science ®Google Scholar
• Ai L , XuA, XuJ. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv. Exp. Med. Biol.1248, 33–59 (2020).
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S , GarrigósC, DuranI. Biomarkers of response to PD-1/PD-L1 inhibition. Crit. Rev. Oncol. Hematol.116, 116–124 (2017).
   PubMed Web of Science ®Google Scholar
• Patel SP , KurzrockR. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther14(4), 847–856 (2015).
   PubMed Web of Science ®Google Scholar
• Xu W , AtkinsMB, McdermottDF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol17(3), 137–150 (2020).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , LuftA, VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• Robert C , LongGV, BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med.372(4), 320–330 (2015).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , PowlesT, BurottoMet al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.384(9), 829–841 (2021).
   PubMed Web of Science ®Google Scholar
• Samstein RM , LeeCH, ShoushtariANet al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet.51(2), 202–206 (2019).
   PubMed Web of Science ®Google Scholar
• Guida A , SabbatiniR, GibelliniL, DeBiasi S, CossarizzaA, PortaC. Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: what are we looking for?Cancer Treat. Rev.94, 102157 (2021).
   PubMed Web of Science ®Google Scholar
• Czyzyk-Krzeska MF , LanderoFigueroa JA, GulatiSet al. Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma. Genes (Basel)12(3), 388 (2021).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS, BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Paver EC , CooperWA, ColebatchAJet al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumors: a guide to immunohistochemistry implementation and interpretation. Pathology53(2), 141–156 (2021).
   PubMed Web of Science ®Google Scholar
• Khunger M , HernandezAV, PasupuletiVet al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis Oncol.1, 1–15 (2017).
   PubMed Web of Science ®Google Scholar
• Carretero-González A , LoraD, MartínSobrino Iet al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel)12(7), 1945 (2020).
   PubMed Web of Science ®Google Scholar
• Motzer R , AlekseevB, RhaSYet al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N. Engl. J. Med.384(14), 1289–1300 (2021).
   PubMed Web of Science ®Google Scholar
• Callea M , AlbigesL, GuptaMet al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res.3(10), 1158–1164 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , RiniBI, McdermottDFet al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol.33(13), 1430–1437 (2015).
   PubMed Web of Science ®Google Scholar
• Yearley JH , GibsonC, YuNet al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin. Cancer Res.23(12), 3158–3167 (2017).
   PubMed Web of Science ®Google Scholar
• Rini BI , PowlesT, AtkinsMBet al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet393(10189), 2404–2415 (2019).
   PubMed Web of Science ®Google Scholar
• Yarchoan M , HopkinsA, JaffeeEM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N. Engl. J. Med.377(25), 2500–2501 (2017).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , RobbinsPB, PowlesTet al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med.26(11), 1733–1741 (2020).
   PubMed Web of Science ®Google Scholar
• Marchetti A , RoselliniM, MollicaVet al. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory? Int. J. Mol. Sci. 22(12), 6237 (2021).
   PubMed Web of Science ®Google Scholar
• Pichler R , CompératE, KlatteTet al. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 11(3), (2019).
   Web of Science ®Google Scholar
• Motzer RJ , RiniBI, McdermottDFet al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol.20(10), 1370–1385 (2019).
   PubMed Web of Science ®Google Scholar
• Powles T , PlimackER, SoulièresDet al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol.21(12), 1563–1573 (2020).
   PubMed Web of Science ®Google Scholar
• Tannir NM , SignorettiS, ChoueiriTKet al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin. Cancer Res.27(1), 78–86 (2021).
   PubMed Web of Science ®Google Scholar
• D’costa NM , CinaD, ShresthaRet al. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Sci. Rep.10(1), 2026 (2020).
   PubMed Web of Science ®Google Scholar
• Yoshida T , OheC, IkedaJet al. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J. Immunother. Cancer9(9), e002922 (2021).
   PubMed Web of Science ®Google Scholar
• Gulati S , VogelzangNJ. Biomarkers in renal cell carcinoma: are we there yet?Asian J. Urol.8(4), 362–375 (2021).
   PubMed Web of Science ®Google Scholar
• Mano R , DuzgolC, GanatMet al. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - an exploratory analysis. Urol. Oncol.39(11), 791.e717–791.e724 (2021).
   Web of Science ®Google Scholar
• Varela I , TarpeyP, RaineKet al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature469(7331), 539–542 (2011).
   PubMed Web of Science ®Google Scholar
• Miao D , MargolisCA, GaoWet al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science359(6377), 801–806 (2018).
   PubMed Web of Science ®Google Scholar
• Braun DA , IshiiY, WalshAMet al. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol.5(11), 1631–1633 (2019).
   PubMed Web of Science ®Google Scholar
• Dai J , CuiY, LiangXet al. PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Front. Genet.13, 1066347 (2022).
   PubMed Web of Science ®Google Scholar
• Kapur P , Peña-LlopisS, ChristieAet al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol.14(2), 159–167 (2013).
   PubMed Web of Science ®Google Scholar
• Joseph RW , KapurP, SerieDJet al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer120(7), 1059–1067 (2014).
   PubMed Web of Science ®Google Scholar
• Li F , AljahdaliIaM, ZhangR, NastiukKL, KrolewskiJJ, LingX. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J. Exp. Clin. Cancer Res.40(1), 254 (2021).
   PubMed Web of Science ®Google Scholar
• Moreira M , PobelC, EpaillardN, SimonaggioA, OudardS, VanoYA. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist.3(3), 454–471 (2020).
   PubMedGoogle Scholar
• Voss MH , ReisingA, ChengYet al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncol.19(12), 1688–1698 (2018).
   PubMed Web of Science ®Google Scholar
• Chen R , ZhaoWQ, FangC, YangX, JiM. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers. J. Cancer11(11), 3349–3356 (2020).
   PubMed Web of Science ®Google Scholar
• Hakimi AA , OstrovnayaI, RevaBet al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res.19(12), 3259–3267 (2013).
   PubMed Web of Science ®Google Scholar
• Zheng X , LinJ, XiongJet al. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy. BMC Cancer23(1), 686 (2023).
   PubMed Web of Science ®Google Scholar
• Liu Y , GouX, WeiZ, YuH, ZhouX, LiX. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma. Aging (Albany NY)12(15), 15359–15373 (2020).
   PubMedGoogle Scholar
• Ho TH , ChoueiriTK, WangKet al. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur. Urol. Focus2(2), 204–209 (2016).
   PubMedGoogle Scholar
• Hagiwara M , FushimiA, MatsumotoK, OyaM. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur. Urol.81(2), 145–148 (2022).
   PubMedGoogle Scholar
• Lanillos J , SantosM, ValdiviaC, MoraA, Rodríguez-AntonaC. Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma. Eur. Urol.82(3), 334–335 (2022).
   PubMed Web of Science ®Google Scholar
• Pan YR , WuCE, WangYCet al. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin. Transl. Immunol.9(7), e1145 (2020).
   PubMed Web of Science ®Google Scholar
• Ricciuti B , RecondoG, SpurrLFet al. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin. Cancer Res.26(15), 4135–4142 (2020).
   PubMed Web of Science ®Google Scholar
• Rizvi H , Sanchez-VegaF, LaKet al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J. Clin. Oncol.36(7), 633–641 (2018).
   PubMed Web of Science ®Google Scholar
• Labriola MK , ZhuJ, GuptaRTet al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J. Immunother. Cancer8(1), e000319 (2020).
   PubMed Web of Science ®Google Scholar
• Gibson BA , KrausWL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol.13(7), 411–424 (2012).
   PubMed Web of Science ®Google Scholar
• Pletcher JP , BhattacharjeeS, DoanJPet al. The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. Front. Oncol.11, 681441 (2021).
   PubMed Web of Science ®Google Scholar
• Ged G , RifkindI, TonyLet al. ORCHID: a phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations. Oncologist28(Suppl. 1), S1 (2023).
   PubMedGoogle Scholar
• Hamada T , SoongTR, MasugiYet al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology7(7), e1442999 (2018).
   PubMed Web of Science ®Google Scholar
• Jansen CS , ProkhnevskaN, MasterVAet al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature576(7787), 465–470 (2019).
   PubMed Web of Science ®Google Scholar
• Eroglu Z , ZaretskyJM, Hu-LieskovanSet al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature553(7688), 347–350 (2018).
   PubMed Web of Science ®Google Scholar
• Johnston MP , KhakooSI. Immunotherapy for hepatocellular carcinoma: current and future. World J. Gastroenterol.25(24), 2977–2989 (2019).
   PubMed Web of Science ®Google Scholar
• Kawashima A , UemuraM, NonomuraN. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma. Clin. Genitourin. Cancer17(6), e1147–e1152 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang S , ZhangE, LongJet al. Immune infiltration in renal cell carcinoma. Cancer Sci.110(5), 1564–1572 (2019).
   PubMed Web of Science ®Google Scholar
• Yao J , XiW, ZhuY, WangH, HuX, GuoJ. Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Cancer Manag. Res.10, 3419–3431 (2018).
   PubMed Web of Science ®Google Scholar
• Nakano O , SatoM, NaitoYet al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res.61(13), 5132–5136 (2001).
   PubMed Web of Science ®Google Scholar
• Carlisle JW , JansenCS, CardenasMAet al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother. Cancer10(7), (2022).
   PubMed Web of Science ®Google Scholar
• Stenzel PJ , SchindeldeckerM, TagschererKEet al. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Transl. Oncol.13(2), 336–345 (2020).
   PubMed Web of Science ®Google Scholar
• Cristescu R , MoggR, AyersMet al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science362(6411), eaar3593 (2018).
   PubMed Web of Science ®Google Scholar
• Ascierto ML , McmillerTL, BergerAEet al. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunol. Res.4(9), 726–733 (2016).
   PubMed Web of Science ®Google Scholar
• Wallin JJ , BendellJC, FunkeRet al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun.7, 12624 (2016).
   PubMed Web of Science ®Google Scholar
• Routy B , LeChatelier E, DerosaLet al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science359(6371), 91–97 (2018).
   PubMed Web of Science ®Google Scholar
• Salgia NJ , BergerotPG, MaiaMCet al. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur. Urol.78(4), 498–502 (2020).
   PubMed Web of Science ®Google Scholar
• Pal SK , LiSM, WuXet al. Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors. Clin. Cancer Res.21(23), 5286–5293 (2015).
   PubMed Web of Science ®Google Scholar
• Derosa L , HellmannMD, SpazianoMet al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol.29(6), 1437–1444 (2018).
   PubMed Web of Science ®Google Scholar
• Dizman N , MezaL, BergerotPet al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med.28(4), 704–712 (2022).
   PubMed Web of Science ®Google Scholar
• Shirasu M , TouharaK. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J. Biochem.150(3), 257–266 (2011).
   PubMed Web of Science ®Google Scholar
• Van De Kant KD , VanDer Sande LJ, JöbsisQ, Van SchayckOC, DompelingE. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir. Res.13(1), 117 (2012).
   PubMedGoogle Scholar
• Janfaza S , KhorsandB, NikkhahM, ZahiriJ. Digging deeper into volatile organic compounds associated with cancer. Biol. Methods Protoc.4(1), bpz014 (2019).
   PubMedGoogle Scholar
• Lagniau S , LamoteK, Van MeerbeeckJP, VermaelenKY. Biomarkers for early diagnosis of malignant mesothelioma: do we need another moonshot?Oncotarget8(32), 53751–53762 (2017).
   PubMedGoogle Scholar
• Hanna GB , BoshierPR, MarkarSR, RomanoA. Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis. JAMA Oncol.5(1), e182815 (2019).
   PubMed Web of Science ®Google Scholar
• De Vries R , MullerM, VanDer Noort Vet al. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. Ann. Oncol.30(10), 1660–1666 (2019).
   PubMed Web of Science ®Google Scholar
• Buma AIG , MullerM, DeVries Ret al. eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. Lung Cancer160, 36–43 (2021).
   PubMed Web of Science ®Google Scholar
• Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response. https://clinicaltrials.gov/study/NCT04146064
   Google Scholar
• Stone L . Urinary VOCs as bladder cancer biomarkers. Nat. Rev. Urol.19(5), 256 (2022).
   Web of Science ®Google Scholar
• Murdocca M , TorinoF, PucciSet al. Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. Cancers (Basel)13(16), (2021).
   PubMed Web of Science ®Google Scholar
• Santoni M , CortelliniA, ButiS. Unlocking the secret of the obesity paradox in renal tumors. Lancet Oncol.21(2), 194–196 (2020).
   PubMed Web of Science ®Google Scholar
• Cortellini A , BersanelliM, SantiniDet al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur. J. Cancer128, 17–26 (2020).
   PubMed Web of Science ®Google Scholar
• Sanchez A , FurbergH, KuoFet al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol.21(2), 283–293 (2020).
   PubMed Web of Science ®Google Scholar
• Wang Z , AguilarEG, LunaJIet al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med.25(1), 141–151 (2019).
   PubMed Web of Science ®Google Scholar
• Indini A , RijavecE, GhidiniMet al. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. Int. J. Mol. Sci.22(5), 2628 (2021).
   PubMed Web of Science ®Google Scholar
• Martini DJ , ShabtoJM, GoyalSet al. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist26(12), 1017–1025 (2021).
   PubMed Web of Science ®Google Scholar
• Martini DJ , OlsenTA, GoyalSet al. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Front. Oncol.11, 707050 (2021).
   PubMed Web of Science ®Google Scholar
• Martini DJ , KlineMR, LiuYet al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer126(3), 575–582 (2020).
   PubMed Web of Science ®Google Scholar
• Bilen MA , MartiniDJ, LiuYet al. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist25(3), e528–e535 (2020).
   PubMed Web of Science ®Google Scholar
• Bagley SJ , KothariS, AggarwalCet al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer106, 1–7 (2017).
   PubMed Web of Science ®Google Scholar
• Nunno VD , MollicaV, GattoLet al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy11(7), 631–643 (2019).
   PubMed Web of Science ®Google Scholar
• Templeton AJ , KnoxJJ, LinXet al. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. Eur. Urol.70(2), 358–364 (2016).
   PubMed Web of Science ®Google Scholar
• Lalani AA , XieW, MartiniDJet al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J. Immunother. Cancer6(1), 5 (2018).
   PubMed Web of Science ®Google Scholar
• Shao Y , WuB, JiaW, ZhangZ, ChenQ, WangD. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol.20(1), 90 (2020).
   PubMed Web of Science ®Google Scholar
• Bilen MA , RiniBI, VossMHet al. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin. Cancer Res.28(4), 738–747 (2022).
   PubMed Web of Science ®Google Scholar
• Bilen MA , DutcherGMA, LiuYet al. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin. Genitourin. Cancer16(3), e563–e575 (2018).
   PubMed Web of Science ®Google Scholar
• Ravindranathan D , MasterVA, BilenMA. Inflammatory Markers in Cancer Immunotherapy. Biology (Basel)10(4), (2021).
   PubMedGoogle Scholar
• Bilen MA , MartiniDJ, LiuYet al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer125(1), 127–134 (2019).
   PubMed Web of Science ®Google Scholar
• Martini DJ , KlineMR, LiuYet al. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat. Res. Commun.28, 100393 (2021).
   PubMedGoogle Scholar
• Zhuang TZ , RavindranathanD, LiuYet al. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist28(3), 239–245 (2023).
   PubMedGoogle Scholar
• Brown JT , LiuY, ShabtoJMet al. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J. Immunother. Cancer9(7), e002851 (2021).
   PubMed Web of Science ®Google Scholar
• Martini DJ , LiuY, ShabtoJMet al. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist25(3), e484–e491 (2020).
   PubMed Web of Science ®Google Scholar
• Smith CG , MoserT, MouliereFet al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med.12(1), 23 (2020).
   PubMed Web of Science ®Google Scholar
• Geertsen L , KoldbyKM, ThomassenM, KruseT, LundL. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. Eur. Urol. Open Sci.37, 27–35 (2022).
   PubMedGoogle Scholar
• Hahn AW , GillDM, MaughanBet al. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget8(20), 33614–33620 (2017).
   PubMedGoogle Scholar
• Pal SK , SonpavdeG, AgarwalNet al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur. Urol.72(4), 557–564 (2017).
   PubMed Web of Science ®Google Scholar
• Nikanjam M , KatoS, KurzrockR. Liquid biopsy: current technology and clinical applications. J. Hematol. Oncol.15(1), 131 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang Q , LuoJ, WuSet al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov.10(12), 1842–1853 (2020).
   PubMed Web of Science ®Google Scholar
• Yu T , WangY, FanYet al. CircRNAs in cancer metabolism: a review. J. Hematol. Oncol.12(1), 90 (2019).
   PubMed Web of Science ®Google Scholar
• Qu S , LiuZ, YangXet al. The emerging functions and roles of circular RNAs in cancer. Cancer Lett.414, 301–309 (2018).
   PubMed Web of Science ®Google Scholar
• Rashedi S , MardaniM, RafatiAet al. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma. J. Clin. Lab. Anal.36(10), e24670 (2022).
   PubMed Web of Science ®Google Scholar
• Dong Y , GaoQ, ChenYet al. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy. Nat. Commun.14(1), 2540 (2023).
   PubMed Web of Science ®Google Scholar
• Franz A , RallaB, WeickmannSet al. Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. Cancers (Basel)11(10), 1473 (2019).
   PubMed Web of Science ®Google Scholar
• Cui X , WangJ, GuoZet al. Emerging function and potential diagnostic value of circular RNAs in cancer. Mol. Cancer17(1), 123 (2018).
   PubMedGoogle Scholar
• Zhang S , ZhangF, NiuY, YuS. Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma. Cancer Manag. Res.13, 6489–6497 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou Y , ZhangZ, WoM, XuW. The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis. Bioengineered12(1), 8994–9005 (2021).
   PubMed Web of Science ®Google Scholar
• Li T , TongH, ZhuJet al. Identification of a Three-Glycolysis-Related lncRNA Signature Correlated With Prognosis and Metastasis in Clear Cell Renal Cell Carcinoma. Front. Med. (Lausanne)8, 777507 (2021).
   PubMed Web of Science ®Google Scholar
• Su Y , ZhangT, TangJet al. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Front. Oncol.11, 640150 (2021).
   PubMed Web of Science ®Google Scholar
• Zhao M , WangS, LiQ, JiQ, GuoP, LiuX. MALAT1: a long non-coding RNA highly associated with human cancers. Oncol. Lett.16(1), 19–26 (2018).
   PubMed Web of Science ®Google Scholar
• Hirata H , HinodaY, ShahryariVet al. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res.75(7), 1322–1331 (2015).
   PubMed Web of Science ®Google Scholar
• Zhai W , MaJ, ZhuRet al. MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br. J. Cancer119(5), 591–604 (2018).
   PubMed Web of Science ®Google Scholar
• Jin C , ShiL, LiKet al. Mechanism of tumor-derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1. Oncol. Rep.46(3), 187 (2021).
   PubMed Web of Science ®Google Scholar
• Li Z , MaZ, XuX. Long non-coding RNA MALAT1 correlates with cell viability and mobility by targeting miR-22-3p in renal cell carcinoma via the PI3K/Akt pathway. Oncol. Rep.41(2), 1113–1121 (2019).
   PubMed Web of Science ®Google Scholar
• Guo R , ZouB, LiangYet al. LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma. Cell Death Dis.12(7), 689 (2021).
   PubMed Web of Science ®Google Scholar
• Tan L , TangY, LiHet al. N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway. Front. Oncol.11, 641833 (2021).
   PubMed Web of Science ®Google Scholar
• Nakken S , EikremØ, MartiHPet al. AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. Cancer Cell Int.21(1), 690 (2021).
   PubMed Web of Science ®Google Scholar
• Fu S , GongB, WangSet al. Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma. Int. J. Gen. Med.14, 8047–8064 (2021).
   PubMed Web of Science ®Google Scholar
• Han S , QiY, XuYet al. lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p. Cancer Cell Int.21(1), 376 (2021).
   PubMed Web of Science ®Google Scholar
• Dong P , XiongY, KonnoYet al. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway. J. Exp. Clin. Cancer Res.40(1), 216 (2021).
   PubMed Web of Science ®Google Scholar
• Li K , SunD, GouQet al. Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Cancer Lett.420, 80–90 (2018).
   PubMed Web of Science ®Google Scholar
• Yue QY , ZhangY. Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Eur. Rev. Med. Pharmacol. Sci.22(4), 1003–1010 (2018).
   PubMed Web of Science ®Google Scholar
• Meng X , SunW, YuJet al. LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer. Mol. Ther. Nucleic Acids22, 1004–1015 (2020).
   PubMedGoogle Scholar
• Yu Y , ZhangW, LiAet al. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Netw. Open3(4), e202149 (2020).
   PubMed Web of Science ®Google Scholar
• Deutsch JS , LipsonEJ, DanilovaLet al. Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Rep. Med.4(2), 100947 (2023).
   PubMedGoogle Scholar
• Mcdermott DF , HuseniMA, AtkinsMBet al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med.24(6), 749–757 (2018).
   PubMed Web of Science ®Google Scholar
• Bi K , HeMX, BakounyZet al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell39(5), 649–661.e645 (2021).
   PubMed Web of Science ®Google Scholar
• Das S , JohnsonDB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer7(1), 306 (2019).
   PubMed Web of Science ®Google Scholar
• Nukaya T , TakaharaK, YoshizawaAet al. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. Clin. Genitourin. Cancer doi: 10.1016/j.clgc.2023.09.007 (2023).
   Web of Science ®Google Scholar
• Ueda K , SuekaneS, KuroseHet al. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn. J. Clin. Oncol.52(5), 479–485 (2022).
   PubMed Web of Science ®Google Scholar
• Martini DJ , GoyalS, LiuYet al. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist26(10), e1742–e1750 (2021).
   PubMed Web of Science ®Google Scholar
• Washino S , ShirotakeS, TakeshitaHet al. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. Int. J. Clin. Oncol.28(12), 1651–1658 (2023).
   PubMed Web of Science ®Google Scholar
• Diehl A , YarchoanM, HopkinsA, JaffeeE, GrossmanSA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget8(69), 114268–114280 (2017).
   PubMedGoogle Scholar
• Ma Y , MaX, WangJ, WuS, WangJ, CaoB. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J. Surg. Oncol.20(1), 242 (2022).
   PubMed Web of Science ®Google Scholar
• Tasaki Y , HamamotoS, SugiyamaYet al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int. J. Urol.30(10), 866–874 (2023).
   PubMedGoogle Scholar
• Ruste V , GoldschmidtV, LaparraAet al. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry. Eur. J. Cancer158, 217–224 (2021).
   PubMedGoogle Scholar
• Michailidou D , KhakiAR, MorelliMP, DiamantopoulosL, SinghN, GrivasP. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci. Rep.11(1), 9029 (2021).
   PubMed Web of Science ®Google Scholar
• Eun Y , KimIY, SunJMet al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep.9(1), 14039 (2019).
   PubMedGoogle Scholar
• Suazo-Zepeda E , BokernM, VinkePC, HiltermannTJN, DeBock GH, SidorenkovG. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol. Immunother.70(11), 3069–3080 (2021).
   PubMed Web of Science ®Google Scholar
• Lee PY , OenKQX, LimGRSet al. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers (Basel)13(6), 1308 (2021).
   PubMed Web of Science ®Google Scholar
• Takada S , MurookaH, TahatsuKet al. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer. Asian Pac. J. Cancer Prev.23(2), 695–701 (2022).
   PubMedGoogle Scholar
• Kizawa R , KunoM, WashinoSet al. 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: musashino study-irAE. Ann. Oncol.33, S1488 (2022).
   Web of Science ®Google Scholar
• Khan S , KhanSA, LuoXet al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer120(1), 63–68 (2019).
   PubMed Web of Science ®Google Scholar
• Tahir SA , GaoJ, MiuraYet al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl Acad. Sci. USA116(44), 22246–22251 (2019).
   PubMed Web of Science ®Google Scholar
• Les I , MartínezM, NarroAet al. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann. Med.53(1), 762–769 (2021).
   PubMed Web of Science ®Google Scholar
• Barth DA , StanzerS, SpiegelbergJet al. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Cancer Med.11(16), 3074–3083 (2022).
   PubMed Web of Science ®Google Scholar
• Bukhari S , HenickBS, WinchesterRJet al. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep. Med.4(1), 100868 (2023).
   PubMedGoogle Scholar
• Kobayashi T , NagataM, IkehataYet al. T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. Curr. Issues Mol. Biol.45(11), 8939–8949 (2023).
   PubMed Web of Science ®Google Scholar
• Liguori L , LucianoA, PolcaroGet al. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series. Biomedicines11(11), 2974 (2023).
   PubMed Web of Science ®Google Scholar
• He S , WangL, SunY, DuH, YuX. Case Report: successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer. Front. Immunol.14, 1270828 (2023).
   PubMedGoogle Scholar